Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Reduced sexual drive may be linked to male breast cancer, while anti-estrogenic factors might lower the risk.

Permanent hair dye use may increase bladder cancer risk, especially in female smokers with certain genetic traits.

X-ray diffraction of hair might help detect breast cancer non-invasively.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

Puerto Rican children with cancer often experience symptoms like irritability, nausea, and hair loss, and need better education and continuous symptom management.

No definitive link between finasteride and male breast cancer, but further research is needed.

Matriptase imbalance contributes to cancer development and spread.

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.

Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.

Chemotherapy causes hair loss in cancer patients by affecting both growing and resting hair.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

High calcium levels in hair may indicate early breast cancer.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Surgeons' testosterone levels significantly increase during major head and neck cancer surgeries.

Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.

PPX causes much less hair loss than traditional taxanes.

Women with pancreatic cancer are more likely to have certain side effects from chemotherapy than men.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Alopecia neoplastica is hair loss from breast cancer spreading to the scalp.

Combining CAF regimen with fufangbanmao capsules improves thyroid cancer treatment outcomes and reduces side effects.

Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.